{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-033594","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.532752+00:00","generated_at":"2026-05-16T05:44:31.297186+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProKidney updates PROACT 1 enrollment target to ~470; confirmatory readout now H2 2029","bullets":["Enrollment target increased to ~470 subjects in Phase 3 PROACT 1 (REGEN-006) study.","Surrogate endpoint (eGFR slope) topline data readout still anticipated Q2 2027.","Confirmatory endpoint (composite time-to-event) topline data readout now anticipated H2 2029.","Statistical powering assumptions unchanged for both surrogate and confirmatory analyses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-033594","json":"https://secwatch.observer/filing/0001193125-26-033594.json","markdown":"https://secwatch.observer/filing/0001193125-26-033594.md","text":"https://secwatch.observer/filing/0001193125-26-033594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526033594/0001193125-26-033594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526033594/prok-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:44:31.297186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}